The hepatoprotective effect of sitagliptin against hepatic ischemia reperfusion-induced injury in rats involves Nrf-2/HO-1 pathway

• Published in: Pharmacological reports Vol. 71; no. 6; pp. 1044 - 1049
• Main Authors: Abdel-Gaber, Seham A., Geddawy, Ayman, Moussa, Rabab A.
• Format: Journal Article
• Language: English
• Published: Cham Elsevier B.V 01.12.2019; Springer International Publishing
• Subjects: Alanine Transaminase - blood; Alanine Transaminase - metabolism; Animals; Apoptosis - drug effects; Aspartate Aminotransferases - metabolism; Drug Safety and Pharmacovigilance; Glutathione - metabolism; Heme oxygenase; Heme Oxygenase-1 - metabolism; Ischemia reperfusion; Liver; Liver - drug effects; Liver - pathology; Male; NF-E2-Related Factor 2 - metabolism; Nrf-2; Original Article; Oxidative Stress - drug effects; Pharmacotherapy; Pharmacy; Rats; Reperfusion Injury - drug therapy; Reperfusion Injury - metabolism; Sitagliptin; Sitagliptin Phosphate - pharmacology; Superoxide Dismutase - metabolism; Sitagliptin; Liver; Ischemia reperfusion; Nrf-2; Heme oxygenase
• ISSN: 1734-1140; 2299-5684
• DOI: 10.1016/j.pharep.2019.06.006

Oxidative stress and inflammation play a key role in the development of hepatic ischemia reperfusion (HIR)-induced injury. Nuclear factor-erythroid 2-related factor-2 (Nrf-2) is a main regulator of numerous genes, encoding cytoprotective molecules including heme oxygenase-1 (HO-1). Sitagliptin (Sit) is an incretin enhancer acting via inhibition of dipeptidyl peptidase-4 (DPP-4) enzyme. This study was undertaken to investigate the ability of Sit to prevent the hepatic pathological changes of HIR induced injury and to modify Nrf-2 and its target HO-1. Pringle's maneuver was used to induce total HIR in adult male rats that were randomly assigned into 4 groups. Group1 (sham-operated control), Group 2 (sham-operated + Sit-control group), Group 3 (HIR non-treated), and Group 4 (HIR + Sit). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities together with hepatic contents of malondialdhyde (MDA), nitric oxide (NO) and reduced glutathione (GSH) and superoxide dismutase (SOD) activity were evaluated. Hepatic tissue mRNA of Nrf-2 and protein content of HO-1 along with histopathological examination and scoring of hepatic injury were performed. Sit caused a significant reduction in ALT and AST activities together with attenuation of HIR-induced histopathological liver injury. Effect of Sit was associated with decreased hepatic level of MDA and NO with increased GSH level and SOD activity. Non-treated rats with HIR showed an increase in Nrf-2 mRNA expression and HO-1 content in hepatic tissue which was further increased by Sit treatment. These results indicate that hepatoprotective activity of Sit against HIR is attributed at least in part to modulation of Nrf-2/ HO-1 signaling pathway.